Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. (CYDY) is a clinical-stage biotechnology and oncology company whose news flow centers on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Company announcements frequently highlight progress in solid tumor oncology, particularly metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC), as well as broader CCR5-related research.
Investors following CYDY news can expect updates on clinical trial milestones, including Phase 2 studies in mCRC and planned Phase 2 proof-of-concept and combination trials in mTNBC. Press releases and shareholder letters describe retrospective survival analyses, PD-L1 upregulation findings, and the company’s “prime and pair” strategy that combines leronlimab with immune checkpoint inhibitors. Conference-related news often covers poster and oral presentations at major oncology meetings such as the San Antonio Breast Cancer Symposium, European Society for Medical Oncology events, and AACR specialty conferences.
CytoDyn’s news stream also includes corporate and regulatory developments. Recent items have addressed the resolution of government investigations, an agreement in principle to settle a securities class action lawsuit, and stockholder approval of amendments to increase authorized common shares. Financing updates, such as the Standby Equity Purchase Agreement with Yorkville, provide insight into how the company plans to support its clinical programs.
In addition, CytoDyn issues periodic letters to shareholders that summarize operational rebuilding, regulatory interactions, and collaborations with academic centers in areas like glioblastoma, Alzheimer’s disease, and HIV cure research. For readers tracking CYDY, this news page offers a consolidated view of scientific data releases, trial progress, financing arrangements, and governance actions that shape the company’s development trajectory.
CytoDyn Inc. (OTC.QB: CYDY) announced an investment community webcast on October 20, 2020, at 2:00 pm PT to discuss the Data Safety Monitoring Committee's recommendations following an interim analysis of 195 patients in its Phase 2b/3 clinical trial for severe-to-critical COVID-19. The webcast will feature a presentation and a Q&A session. The event is accessible via the company's website and will be archived for 30 days after the event.
CytoDyn Inc. (OTC.QB: CYDY) announced an upcoming investment community webcast on October 20, 2020, to discuss recommendations from the Data Safety Monitoring Committee (DSMC) based on an interim analysis of the Phase 2b/3 trial for severe-to-critical COVID-19. Key management, including President Nader Pourhassan, will provide insights into a potential regulatory path forward. The webcast will feature a presentation followed by a Q&A session. Access will be through CytoDyn's corporate website, with replay available for 30 days.
CytoDyn (OTC.QB: CYDY) announced the appointment of Chiral Pharma Corporation to register leronlimab (PRO 140) for potential COVID-19 treatment approval in the Philippines. The company is conducting Phase 2 and Phase 3 trials for COVID-19, with interim results expected mid-October. Leronlimab has received Fast Track designation for indications in HIV and metastatic triple-negative breast cancer. The drug has shown promising results in multiple clinical trials, significantly reducing HIV viral load and tumor metastasis.
CytoDyn Inc. (OTC.QB: CYDY) announces its 2020 Virtual Annual Meeting of Stockholders, scheduled for September 30, 2020, at 9:30 am PT. Due to health concerns from the coronavirus pandemic, in-person attendance is not allowed. Stockholders can log in to participate via the provided webcast link, and questions can be submitted online during the meeting with the passcode CYDY2020. Dr. Nader Pourhassan, CEO, will present a company overview post-business session, with materials available on the company website.